Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Quanterix Corporation (QTRX) Stock Down -11.59% Today?

Why Is Quanterix Corporation (QTRX) Stock Down -11.59% Today?

Key Takeaways

  • Quanterix Corporation (QTRX) fell 11.59%, or $0.24, to $1.825 in midday trading, extending a two-day collapse.
  • The primary catalyst remains the abrupt departure of President and CEO Everett Cunningham, announced before Wednesday's open, with no permanent successor named.
  • Secondary pressure came from a fresh 52-week low at $1.765 and an unresolved debate over the company's shrinking revenue base and cash burn.
  • The selling was company-specific; the move diverged from a broadly steadier life science tools group rather than tracking a sector-wide selloff.
  • News Significance Score: 42/100 — A material governance shock for a sub-$100 million company, compounded by a move roughly 2.7 times its typical daily swing.
  • Traders are watching whether the interim CEO stabilizes the Alzheimer's diagnostics rollout and whether the $70 million year-end cash target holds.
  • Deeper detail on valuation, guidance and consensus numbers is available on the Price Targets, Earnings and Forecast pages.
  • Readers tracking systematic strategies can review the curated Trending AI Robots section for currently top-performing bots.

Quanterix Extends Its Post-Exit Slide

Quanterix Corporation (QTRX) is a Billerica, Massachusetts-based life sciences toolmaker whose Simoa ultrasensitive protein detection platform and spatial biology instruments serve research labs, biopharma partners and, increasingly, clinical diagnostics — most visibly its LucentAD blood-based Alzheimer's tests. Shares traded at $1.825 in Thursday's session, down 11.59% from the prior close of $2.07, after touching $1.765, a new 52-week low. The direction is unambiguously lower, and the decline is a continuation of Wednesday's 27.6% plunge rather than a reversal. The immediate reason markets cite is the sudden exit of the chief executive, announced Wednesday morning, though no new company-specific disclosure has been issued Thursday.

Abrupt CEO Departure Leaves a Leadership Vacuum

Quanterix disclosed Wednesday that Everett Cunningham had stepped down as president, chief executive and board member effective immediately to take another role elsewhere in healthcare, roughly ten months after starting the job. The board named Chief Commercial Officer Jim Gute — himself only appointed in August 2026 — as interim president and CEO and has hired a search firm, with Cunningham remain available through December 11 to support the transition.

The market reaction reflects governance risk more than an operational shock: a company mid-way through a commercial turnaround and a diagnostics build-out now has an interim leader with limited tenure and no confirmed timeline for a permanent replacement. The board reaffirmed the 2026 outlook, which limited the damage on Wednesday but did not halt the follow-through selling on Thursday.

Third-Quarter Results Still Anchor Sentiment

The leadership change landed nine days after third-quarter results that were mixed. Revenue of $35.0 million beat consensus and rose 6.3% sequentially, with spatial consumables near record levels and LucentAD test volumes roughly doubling quarter over quarter. But revenue was still down 13.1% year over year, the net loss was $21.6 million, and adjusted EBITDA remained negative at $12.2 million. Management narrowed full-year revenue guidance to $142–$146 million, with non-GAAP gross margin of 48%–50%, and projected roughly $70 million of cash at year-end after about $16.2 million of quarterly cash usage.

That combination — sequential improvement against a still-declining annual base and continued cash consumption — leaves little margin for execution error, and it amplifies the impact of a leadership surprise. An insider buying pattern and a modest $3.33 average analyst target have not been enough to arrest the slide.

Market Context and Trading Activity

Volume has been heavy: roughly 3.5 million shares traded Wednesday, about five to six times the 20-day average near 620,000, and Thursday's turnover of close to 900,000 shares by midday kept activity elevated versus normal. The stock is far below its 50-day moving average around $3.05 and its 200-day average near $3.61, and the break of the prior $2.045 low is a technically significant event that tends to invite momentum-driven selling. Short interest of about 4.56 million shares, equal to more than ten days of average volume, adds sensitivity to further weakness. The move was idiosyncratic — life science tools peers were mixed to firmer — so this is a single-name repricing, not a sector or index story.

News Significance Score

The score runs from 0, meaning no meaningful news and a move normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Quanterix scores 42 out of 100. The verified news is substantive for a company of this size — an unplanned CEO exit with an interim replacement and no permanent successor, layered on a quarter that still showed a double-digit annual revenue decline — but guidance was reaffirmed and no fundamental asset was lost. The price move was roughly 2.7 times the stock's typical daily swing of about 4.3%, and only two of the past 60 sessions produced an equal or larger move. Strong-but-not-transformative news plus a moderately unusual move combine into a mid-range score.

What Comes Next for QTRX

Attention now turns to the permanent CEO search and whether the board promotes internally or recruits externally. Operationally, investors will watch LucentAD reimbursement momentum — Florida Medicaid coverage took effect November 1 at roughly $480 per test — new clinical reference lab partnerships, and the company's targeted 2027 submission for an in vitro diagnostic claim on its HD-X instrument. Fourth-quarter and full-year 2026 results, expected in the first quarter of 2027, will be the first test of the reaffirmed $142–$146 million revenue range and the roughly $70 million year-end cash target. Risks include continued cash consumption, competitive pressure in Alzheimer's blood testing from already-approved rivals, thin analyst coverage and the possibility of further management turnover before a permanent leader is installed.

Trending AI Robots

Tickeron operates hundreds of AI trading bots spanning thousands of tickers, but the Trending AI Robots page narrows that universe to the strategies performing strongest under current market conditions. The bots differ widely by approach, holding period, risk profile, traded symbols and performance metrics, so the curated list changes as market regimes shift. For traders who want to see which automated strategies are working right now, it is a practical starting point for further research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: QTRX

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


QTRX in -12.80% downward trend, sliding for three consecutive days on November 12, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where QTRX declined for three days, in 299 of 340 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QTRX as a result. In 76 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for QTRX turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

QTRX moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for QTRX crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for QTRX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +22.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTRX advanced for three days, in 209 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

QTRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 128 of 144 cases where QTRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.577) is normal, around the industry mean (4.142). P/E Ratio (-1.105) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.894) is also within normal values, averaging (40.124).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. QTRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -16%. POAS experienced the highest price growth at 158%, while LFWD experienced the biggest fall at -44%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 63
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of protein diagnostic platform

Industry MedicalNursingServices

Industry
Pharmaceuticals Major
Address
900 Middlesex Turnpike
Phone
+1 617 301-9400
Employees
151
Web
https://www.quanterix.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.